Overall, it is noteworthy that groups treated with multi-PPAR agonists demonstrated greater mean improvements and more pronounced reductions in biochemical markers compared with those receiving selective PPAR agonists, underscoring the potential advantage of multiagents in the management of PBC. The gene discussed is PPARA; the disease is primary biliary cholangitis.